Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Organisation › Details

Ziarco Group Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, is an oral histamine H4 receptor antagonist. Ziarco has successfully completed a Phase 2a study in atopic dermatitis and a Phase 2a study in psoriasis is ongoing with data expected in H1 2017. ZPL-521, a topical cPLA2 inhibitor, is being developed for moderate to severe inflammatory skin diseases and is targeted to start a clinical study in atopic dermatitis in mid- 2016, with data due in H1 2017. Ziarco’s investors include Biotechnology Value Fund L.P. and other affiliates of BVF Partners L.P., Pfizer Venture Investments, New Enterprise Associates, Lundbeckfond Ventures and Amgen Ventures. Founded in October 2012, the Company is based in Discovery Park, Sandwich, UK. *


Period Start 2014-11-10 existent
  Group Novartis (Group)
Products Industry anti-inflammatory drug
  Industry 2 antiallergic
Persons Person Yeadon, Mike (Ziarco Pharma 201211– CEO + founder before Pfizer Research UK)
  Person 2 Shivji, Arif (Ziarco Pharma 201211– VP + Head Developm Operations + BusDev + founder before Pfizer Research UK)
Region Region Sandwich, Kent
  Country United Kingdom (GB)
  Street Ramsgate Road
Discovery Park, Innovation House, Office 49
  City CT13 9ND Sandwich, Kent
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: 
Record changed: 2018-10-31


Picture [iito] Made Without Love 650x80px

More documents for Novartis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Global Partnering Four Events One Price 650x80

» top